Helix BioPharma Bolsters Leadership for U.S. Listing and Lung Cancer Trial

Helix BioPharma Corp., a clinical-stage oncology company, announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations. These strategic hires strengthen the executive leadership team as Helix prepares for its planned U.S. securities exchange listing and advances L-DOS47, its lead antibody-enzyme conjugate, into the next stage of development through the LDOS007 study. This Phase IB/Randomized Phase II trial targets first-line non-small cell lung cancer (NSCLC). The company is also building the legal, governance, and operational infrastructure to support its growth phase.

Helen Middleton brings over 30 years of experience in pharmacy, law, and life sciences, having held senior roles at firms like Sidley Austin LLP and companies like Mundipharma International. As General Counsel, she will oversee legal affairs, governance, compliance, and strategic transactions. David Browning, with more than 30 years in global clinical development, has led over 30 Phase I-III studies across multiple oncology modalities. He will lead operational planning and execution for Helix's clinical programs, including LDOS007. CEO Thomas Mehrling emphasized that these appointments are critical as the company executes its capital markets roadmap, including preparing a base shelf prospectus and completing auditor reviews. The new executives expressed enthusiasm for Helix's clinical foundation and growth prospects.

Helix BioPharma's pipeline includes Tumor Defense Breaker™ L-DOS47, which targets CEACAM6-expressing tumors, and next-generation bi-specific ADCs. Other candidates are LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, an oral gemcitabine prodrug. The company is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, visit https://www.helixbiopharma.com/. This news was distributed by NEWMEDIAWIRE.